Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.
about
Somatic DNA mutation analysis in targeted therapy of solid tumoursMEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapyManaging Side Effects of Vemurafenib Therapy for Advanced MelanomaPathways and therapeutic targets in melanomaTargeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondRaf-interactome in tuning the complexity and diversity of Raf function.Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaParadoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cellsResistance to Raf inhibition in cancer.Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.Effects of BRAF mutations and BRAF inhibition on immune responses to melanomaMetabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 SignalingMolecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case reportBRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape.Combination Therapies for Melanoma: A New Standard of Care?Genetics and epigenetics of melanoma.New RAF kinase inhibitors in cancer therapy.Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.MAPK pathway inhibition in melanoma: resistance three ways.Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma.Vemurafenib for the treatment of BRAF mutant metastatic melanoma.The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox.Trametinib in metastatic melanoma.Vemurafenib-induced progression of breast cancer: a case report and review of the literature.HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.BRAF inhibitor-associated cutaneous squamous cell carcinoma: new mechanistic insight, emerging evidence for viral involvement and perspectives on clinical management.The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.MicroRNAs in melanoma development and resistance to target therapy.Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations.KSR as a therapeutic target for Ras-dependent cancers.Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer.Molecular mechanisms supporting a pathogenic role for human polyomavirus 6 small T antigen: Protein phosphatase 2A targeting and MAPK cascade activation.Optimizing the treatment of BRAF mutant melanoma.MALT1 promotes melanoma progression through JNK/c-Jun signalingXL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.Knock-in(g) RAF for a loop.Management of intracranial melanomas in the era of precision medicine.
P2860
Q26770324-7DAC1B5C-EA89-486B-AF88-AAEDF44945E6Q26771192-A923843B-7BBE-4879-97C5-41BFA78D7936Q26795510-CD0D2F91-AC7D-4C1A-A2DA-5EF4B3AE0DC8Q26865736-6FF4EF29-14D2-4DDB-847D-A4C90B437D63Q27026323-8DC2426F-84CF-4688-98D9-561C96596EFEQ27692653-DBEE2E0A-FFAA-4E97-BEEB-CE4284FD0370Q27853209-B4C30BB2-238C-439E-8179-FBC6DF80961CQ28833514-805A2770-7C78-4806-9F13-25450D064046Q33651779-885FF959-2965-4089-89C9-19884EBA8CAFQ34100838-C358DA3D-2E4C-4B37-A737-4E8900E97160Q34646279-FC4D26B0-A3AB-41E2-9488-6E50A03CEAEFQ35931606-15581418-4451-45E8-8124-DB9CE9355FD7Q36123511-EA60976B-70B8-4410-9A9D-420F988AC943Q36289114-91212798-1721-4066-97A5-2EE1981560FFQ36723055-2F476CFA-68FB-4DB7-BF56-9DBBAFA9FD37Q37406812-F115698C-EFCC-46D6-81CC-19BF67DE0928Q38207082-086BE67B-FD76-42C8-A277-DBBDE0DA65A2Q38228386-0B5081DD-6563-4767-8F0F-AF209B7BC1FCQ38238597-09B25BF1-3F4F-45AE-8965-7C3A4ADE8D06Q38241987-056800A7-7E0E-49D4-8EDA-F3388BA4B063Q38357122-04931A85-81E9-411F-9226-33DFC13F8CC3Q38412577-F360D1AD-230B-44B7-9513-8419BFC2E4DBQ38536713-DF9A8819-8FAB-42BA-86D4-18288779756FQ38564626-D8C56751-B4D6-420C-833A-A787D37F9575Q38705011-64C72EAD-25C9-492F-B2CC-E5F3A3C8BB04Q38764961-E5E9B23A-70CB-43A9-81B7-39C9B73C7B7AQ38843111-BF077CA4-F4D1-479A-8FBD-04AE67E81742Q38911486-EA3CDD01-0A82-43B4-AB0E-B4D9651A3243Q39101272-5D76F38E-86EF-4DB5-A33A-4475CB3A9AA0Q39173195-AB67528A-24BD-404A-B11C-FAC917A784F3Q39195762-14733511-4065-45E4-A48C-F61C808D6698Q39319162-76363ED6-C673-4618-9E6A-6F579C530E2AQ40214541-77A783B3-9A56-425F-B82A-79F1BE0C71E2Q40579796-2A6C876A-F798-46E0-B7D0-2358061DC7D2Q40842838-C58C8AC7-1E5C-4765-BE5A-A1CD5E236707Q41228856-3955D99A-C77A-4556-8E0C-2BE844ED1449Q41897553-CBBA39DA-F55D-4DB2-9C0E-BBDEE005BD38Q42333715-E74801F1-2DFF-417E-BF69-449C4A66CEB3Q43080613-C6398DD8-5367-4EFE-8BAD-93ADB1713561Q44959749-89EFF547-8C6A-4775-959C-755B23B1FF0F
P2860
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.
@en
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.
@nl
type
label
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.
@en
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.
@nl
altLabel
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma
@en
prefLabel
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.
@en
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.
@nl
P2093
P2860
P1476
Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma.
@en
P2093
Geoffrey T Gibney
Inna V Fedorenko
Jane L Messina
Vernon K Sondak
P2860
P304
P356
10.1038/NRCLINONC.2013.83
P407
P577
2013-05-28T00:00:00Z